Novel HER2-Targeted Peptide for NIR-II Imaging of Tumor
文献类型：期刊论文
| 作者 | Cao, Rui3; Li, Renda3; Shi, Hui2; Liu, Hongguang3; Cheng, Zhen1,2 |
| 刊名 | MOLECULAR PHARMACEUTICS
 |
| 出版日期 | 2023-02-06 |
| 卷号 | 20期号:2页码:1394-1403 |
| 关键词 | NIR-II peptide HER2 tumor optical imaging |
| DOI | 10.1021/acs.molpharmaceut.2c00964 |
| 文献子类 | Article |
| 英文摘要 | Molecular targets serve a crucial role in drug development. Herein, we discovered a novel peptide that can specifically target the human epidermal growth factor receptor 2 (HER2) and thus named it Herceptide. In our study, Herceptide was conjugated to the near-infrared fluorescent dye indocyanine green (ICG) to obtain a probe, ICG-Herceptide. Importantly, specific binding to HER2 was revealed by molecular docking, surface plasmon resonance analysis, and competition assays. The probe showed high binding affinity (KD = 1.03 nM) and fast binding property (kon = 0.44 min-1). In vivo near-infrared window two (NIR-II, 1000-1700 nm) imaging in HER2-overexpressed SKOV3 tumor-bearing mice demonstrated a high tumor-to-normal tissue signal ratio (T/N = 7.3) at 8 h postinjection. In the blocking study, ICG-Herceptide coinjected with Herceptide only showed a weak tumor signal. In other HER2 high-expression tumors, such as non-small-cell lung cancer A549 and gastric cancer MKN45, the tumor-to-normal tissue signal ratios (T/N) were 4.1 and 4.7, respectively. In contrast, HER2 low-expression tumor MDAMB231 shows no imaging contrast between the tumor and normal tissues. Furthermore, tumor resection was successfully performed under the guidance of the ICG-Herceptide-based NIR-II imaging in subcutaneous SKOV3 mice models. The biocompatibility study indicated that the probe had no observable toxicity to cells and tissues. Overall, these results demonstrate that ICG-Herceptide is a promising optical probe for the diagnosis and localization of HER2-overexpressing tumors. Moreover, Herceptide is a novel HER2-targeting peptide and can be further used for developing theranostic agents. |
| WOS关键词 | HER2 EXPRESSION ; BREAST-CANCER ; THERAPY |
| WOS研究方向 | Research & Experimental Medicine ; Pharmacology & Pharmacy |
| 语种 | 英语 |
| WOS记录号 | WOS:000927727500001 |
| 出版者 | AMER CHEMICAL SOC |
| 源URL | [http://119.78.100.183/handle/2S10ELR8/309704]  |
| 专题 | 新药研究国家重点实验室 |
| 通讯作者 | Shi, Hui; Liu, Hongguang; Cheng, Zhen |
| 作者单位 | 1.Bohai Rim Adv Res Inst Drug Discovery, Shandong Lab Yantai Drug Discovery, Yantai 264117, Shandong, Peoples R China 2.Chinese Acad Sci, Shanghai Inst Mat Med, Mol Imaging Ctr, State Key Lab Drug Res, Shanghai 201203, Peoples R China; 3.Northeastern Univ, Inst Mol Med, Coll Life & Hlth Sci, Shenyang 110167, Peoples R China; |
| 推荐引用方式 GB/T 7714 | Cao, Rui,Li, Renda,Shi, Hui,et al. Novel HER2-Targeted Peptide for NIR-II Imaging of Tumor[J]. MOLECULAR PHARMACEUTICS,2023,20(2):1394-1403. |
| APA | Cao, Rui,Li, Renda,Shi, Hui,Liu, Hongguang,&Cheng, Zhen.(2023).Novel HER2-Targeted Peptide for NIR-II Imaging of Tumor.MOLECULAR PHARMACEUTICS,20(2),1394-1403. |
| MLA | Cao, Rui,et al."Novel HER2-Targeted Peptide for NIR-II Imaging of Tumor".MOLECULAR PHARMACEUTICS 20.2(2023):1394-1403. |
入库方式： OAI收割
来源：上海药物研究所
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。